close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

43.55 +0.87 (+2.03%)
Streaming Delayed Price Updated: 10:19 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
From Pomerantz LLP
Via GlobeNewswire
News headline image
WGS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
GeneDx Holdings Corp (NASDAQ:WGS) Plunges 44% After Disastrous Q1 2026 Miss ↗
Via Chartmill
News headline image
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
GENEDX HOLDINGS CORP. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
One of these stocks plummeted 49% on Tuesday. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
GeneDx Holdings Corp. (WGS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into GeneDx Holdings Corp. (WGS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
Why GeneDX Stock Is Plummeting Today ↗
GeneDX's latest quarterly report arrived with a lot of bad news for investors. 
Via The Motley Fool
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
GeneDx (WGS) Q1 2026 Earnings Transcript ↗
GeneDx (WGS) Q1 2026 Earnings Transcript 
Via The Motley Fool
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
From GeneDx
Via Business Wire
News headline image
GeneDx (WGS) Q1 2025 Earnings Call Transcript ↗
GeneDx (WGS) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
GeneDx (WGS) Q2 2025 Earnings Transcript ↗
GeneDx (WGS) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026
From GeneDx
Via Business Wire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Three stocks that have fallen more than 23% this year were on the Ark Invest CEO's shopping radar on Tuesday. 
Via The Motley Fool
Topics ETFs
News headline image
Landmark Study Shows Average Cost Savings of $80,000 Per Child and Overall Improved Health Outcomes Following GeneDx Exome and Genome Testing
From GeneDx
Via Business Wire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest's CEO kicked off the new trading week with a little shopping. 
Via The Motley Fool
News headline image
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C
From GeneDx
Via Business Wire
News headline image
GeneDx to Present 18 Abstracts at ACMG 2026, Showcasing the Scale of GeneDx Infinity™ and Real-World Genomic Leadership
From GeneDx
Via Business Wire
News headline image
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally ↗
MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend. 
Via The Motley Fool
Topics Energy
News headline image
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell? ↗
AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data analytics platform. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today